moderate - While drug discovery spending by large pharma is relatively recession-resistant, biotech funding cycles are highly sensitive to risk appetite and growth stock valuations. Economic downturns reduce venture capital availability for follow-on financings and compress biotech valuations, creating existential risk for pre-revenue companies. However, pharmaceutical R&D budgets (Absci's customer base) tend to be more stable through cycles as large-cap pharma maintains strategic innovation priorities.

High sensitivity to interest rates through multiple channels: (1) As a pre-revenue growth company, Absci's valuation is based on discounted future cash flows 5-10+ years out, making it extremely sensitive to discount rate changes - rising rates compress NPV of distant milestones; (2) Higher rates reduce risk appetite for speculative biotech, contracting sector multiples; (3) Financing costs increase for future capital raises, though current debt is minimal (0.03 D/E). The 10-year Treasury yield directly impacts comparable biotech valuations and investor willingness to fund cash-burning platforms.

growth - Attracts highly speculative, venture-style public market investors willing to accept binary outcomes and multi-year timelines for platform validation. The stock appeals to thematic AI/biotech crossover investors betting on computational biology disruption, but requires high risk tolerance given pre-revenue status, cash burn, and lack of clinical proof points. Not suitable for value or income investors given negative margins and no path to near-term profitability.